Direct 18F-Folate Radiolabeling via Nucleophilic Substitution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing 18F-labeled folate radiopharmaceuticals are time-consuming and yield low radiochemical yields due to the difficulty in direct radiolabeling of folic acid with fluorine-18, requiring multi-step processes and intermediates.
Innovation Solution
A direct radiolabeling method using 18F-fluoride with phase transfer catalysts like tetrabutylamonium carbonate or aminopolyethers, allowing for efficient attachment of fluorine-18 to folic acid or derivatives without the need for prosthetic groups or intermediate separation, facilitating regioselective labeling of α- or γ-isomers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multi-step synthesis processes with intermediates are used to label folic acid with 18F, then the radiolabeling can be achieved, but the synthesis time increases and radiochemical yields decrease
Solution Approach 1:
The patent extracts and eliminates the unnecessary intermediate steps from the conventional multi-step synthesis process. By using a direct nucleophilic substitution reaction where 18F-fluoride directly replaces a leaving group on the folic acid derivative, the method removes the need for prosthetic groups and intermediate separation steps, thereby reducing synthesis time and improving radiochemical yield
Solution Approach 2:
Instead of following the conventional approach of first activating folic acid with prosthetic groups and then labeling with 18F, the patent inverts the sequence by directly introducing 18F onto the folic acid derivative through nucleophilic substitution. This reversal of the traditional synthesis pathway eliminates complex intermediate steps and achieves higher efficiency
2Loss of time
If direct radiolabeling with 18F-fluoride is attempted on conventional folic acid structures, then synthesis time can be reduced, but the labeling efficiency decreases due to structural incompatibility
Solution Approach 1:
The patent applies local quality modification by introducing a specific leaving group (such as triflate, tosylate, or mesylate) at a specific position on the folic acid derivative structure. This localized structural modification at the labeling site enables direct nucleophilic substitution with 18F-fluoride while maintaining the overall folic acid structure's biological activity, thereby achieving both time reduction and high labeling efficiency
Solution Approach 2:
The patent changes the chemical parameters of the folic acid structure by incorporating electron-withdrawing groups and appropriate leaving groups that enhance the electrophilicity of the labeling position. These parameter changes make the molecule more reactive toward nucleophilic 18F-fluoride, enabling efficient direct labeling without requiring multi-step activation processes
3Ease of manufacture
If conventional radiolabeling methods are used, then the process can be standardized, but the complexity of the synthesis procedure increases due to intermediate separation and purification steps
Solution Approach 1:
The patent merges the radiolabeling step with the final product formation step by using direct nucleophilic substitution. This consolidation eliminates the need for separate intermediate purification and activation steps, reducing process complexity while maintaining ease of manufacture through a streamlined single-step labeling procedure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a time-saving and efficient synthesis of 18F-labeled folate radiopharmaceuticals with higher radiochemical yields, enabling effective diagnostic imaging and therapy monitoring of cancer and inflammatory diseases.
Implementation Method 1
fluorine-18 is attached to a pteroate (or folate) or derivative thereof through direct radiolabeling with 18[F]fluoride
Implementation Method 2
A direct radiolabeling method using 18F-fluoride with phase transfer catalysts like tetrabutylamonium carbonate or aminopolyethers
Data Source
AI summary
The present invention is directed towards a new method of synthesis of 18F-folate radiopharmaceuticals, wherein fluorine-18 is attached to a pteroate (or folate) or derivative thereof, through direct radiolabeling with 18[F]fluoride, as well as 18F-folate radiopharmaceuticals obtained by such method of synthesis and their use in diagnosis and monitoring of cancer therapy and therapy of inflammatory and autoimmune diseases.